Support for a Biotech Company entering the french market with an orphan drug.
We are pioneers in the utilisation of Multi-Criteria Decision Analysis (MCDA) at international and national level, helping evaluation committees to assess the relative additional value contribution of new health technology and helping companies to better position their product with respect to existing alternatives.
RPN has experience with a wide range of therapeutic areas and particularly with orphan and advanced-therapy medicinal products. RPN support includes early access and P&MA strategic assessments, advisory boards, stakeholder management and full support with national and regional P&R negotiations.
SmartStep Healthcare Strategy & Market Access Consulting provides personalized and specialized consulting services to the pharmaceutical and medical device industries to provide fast and effective market access to their products in Germany.